Literature DB >> 31081072

Long non-coding RNA ZFAS1 regulates NOB1 expression through interacting with miR-646 and promotes tumorigenesis in osteosarcoma.

C-W Liu1, D Liu, D Peng.   

Abstract

OBJECTIVE: Zinc finger antisense 1 (ZFAS1), a newly identified lncRNA, is aberrantly regulated in various cancers including osteosarcoma (OS). However, the underlying molecular mechanisms of ZFAS1 in OS remain to be elucidated.
MATERIALS AND METHODS: We used transfection, luciferase report assay, quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), colony formation assay, transwell migration, invasion assays, and Western blot to determine the potential mechanisms.
RESULTS: Our study showed that ZFAS1 was up-regulated in OS cells and promoted the colony formation, migration, and invasion of OS cells via activating the MAPK signaling pathway. Furthermore, the experimental results indicated that miR-646 was a target of ZFAS1 and there was a negative relationship between ZFAS1 and miR-646 expression. Additionally, we found that ZFAS1 in OS cells up-regulated the expression of NOB1 through sponging miR-646, finally facilitating the growth of the OS cells.
CONCLUSIONS: These results demonstrated that ZFAS1/miR-646/NOB1 axis might play an important role in the development of OS, and ZFAS1 and miR-646 can be considered as potential biomarkers for the diagnosis and treatment of OS.

Entities:  

Year:  2019        PMID: 31081072     DOI: 10.26355/eurrev_201904_17679

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

Review 1.  The Role of NcRNAs to Regulate Immune Checkpoints in Cancer.

Authors:  Yicun Jiang; Leilei Zhao; Yiwen Wu; Sijun Deng; Pu Cao; Xiaoyong Lei; Xiaoyan Yang
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

2.  Knockdown of LncRNA RHPN1-AS1 Inhibits Cell Migration, Invasion and Proliferation in Head and Neck Squamous Cell Carcinoma.

Authors:  Xiaowen Qiu; Zhuo Lei; Zeyou Wang; Yuming Xu; Chang Liu; Panchun Li; Hanjiang Wu; Zhaojian Gong
Journal:  J Cancer       Date:  2019-07-05       Impact factor: 4.207

3.  LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis.

Authors:  Dong Fu; Chunwen Lu; Xingzhou Qu; Peng Li; Kai Chen; Liancheng Shan; Xiaodong Zhu
Journal:  Aging (Albany NY)       Date:  2019-10-10       Impact factor: 5.682

4.  Doxorubicin inhibits osteosarcoma progression by regulating circ_0000006/miR-646/ BDNF axis.

Authors:  Abulimiti Amuti; Dehu Liu; Ayiguli Maimaiti; Yao Yu; Yalikun Yasen; Haoguang Ma; Rui Li; Shurong Deng; Fei Pang; Youliang Tian
Journal:  J Orthop Surg Res       Date:  2021-10-30       Impact factor: 2.359

5.  Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3.

Authors:  Yang Zhang; Wenbo Xu; Yanlong Wang; Jianming Li; Guanyi He; Mingyan Guan; Xiangyu Zeng; Wei Bian; Yan Song; Jianyu Liu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 6.  Long noncoding RNAs in osteosarcoma via various signaling pathways.

Authors:  Jinming Han; Xiaohan Shen
Journal:  J Clin Lab Anal       Date:  2020-04-06       Impact factor: 2.352

7.  circRNA circ-CCND1 promotes the proliferation of laryngeal squamous cell carcinoma through elevating CCND1 expression via interacting with HuR and miR-646.

Authors:  Yanzi Zang; Jing Li; Baoluo Wan; Yong Tai
Journal:  J Cell Mol Med       Date:  2020-01-17       Impact factor: 5.310

8.  Silencing lncRNA ZFAS1 or elevated microRNA-135a represses proliferation, migration, invasion and resistance to apoptosis of osteosarcoma cells.

Authors:  Zilong Zhao; Xiafei Lin; Yunhui Tong; Wenxia Li
Journal:  Cancer Cell Int       Date:  2019-12-03       Impact factor: 5.722

9.  hsa_circ0021347 as a Potential Target Regulated by B7-H3 in Modulating the Malignant Characteristics of Osteosarcoma.

Authors:  Ling Wang; Guo-Chuan Zhang; Fu-Biao Kang; Long Zhang; Ying-Ze Zhang
Journal:  Biomed Res Int       Date:  2019-12-17       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.